Review decision – March 2021

Decision that the existing guidance remains relevant and an update is not needed

We would like to update you on the decision made regarding the review of the existing guidance on TA306; Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma.

No substantial new evidence has been identified that would be likely to change the current recommendation in TA306.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA306 will not be updated at this time.

Review decision paper

Stakeholder List

This page was last updated: